{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:21:40Z","timestamp":1787030500329,"version":"build-2736575974"},"reference-count":47,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012357","name":"LifeArc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012357","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Evgen"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,1,15]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Sulforaphane can induce the transcription factor, Nrf2, promoting antioxidant and anti-inflammatory responses. In this study, hospitalised patients with community-acquired pneumonia (CAP) were treated with stabilised synthetic sulforaphane (SFX-01) to evaluate impact on clinical status and inflammation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Double-blind, randomised, placebo-controlled trial of SFX-01 (300\u2005mg oral capsule, once daily for 14\u2005days) conducted in Dundee, UK, between November 2020 and May 2021. Patients had radiologically confirmed CAP and CURB-65 (confusion, urea &gt;7\u2005mmol\u00b7L<jats:sup>-1<\/jats:sup>, respiratory rate \u226530\u2005breaths\u00b7min<jats:sup>-1<\/jats:sup>, blood pressure &lt;90\u2005mmHg (systolic) or \u226460\u2005mmHg (diastolic), age \u226565\u2005years) score \u22651. The primary outcome was the seven-point World Health Organization clinical status scale at day 15. Secondary outcomes included time to clinical improvement, length of stay and mortality. Effects on Nrf2 activity and inflammation were evaluated on days 1, 8 and 15 by measurement of 45 serum cytokines and mRNA sequencing of peripheral blood leukocytes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The trial was terminated prematurely due to futility with 133 patients enrolled. 65 patients were randomised to SFX-01 treatment and 68 patients to placebo. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was the cause of CAP in 103 (77%) cases. SFX-01 treatment did not improve clinical status at day 15 (adjusted OR 0.87, 95% CI 0.41\u20131.83; p=0.71), time to clinical improvement (adjusted hazard ratio (aHR) 1.02, 95% CI 0.70\u20131.49), length of stay (aHR 0.84, 95% CI 0.56\u20131.26) or 28-day mortality (aHR 1.45, 95% CI 0.67\u20133.16). The expression of Nrf2 targets and pro-inflammatory genes, including interleukin (IL)-6, IL-1\u03b2 and tumour necrosis factor-\u03b1, was not significantly changed by SFX-01 treatment. At days 8 and 15, respectively, 310 and 42 significant differentially expressed genes were identified between groups (false discovery rate adjusted p&lt;0.05, log<jats:sub>2<\/jats:sub>FC &gt;1).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SFX-01 treatment did not improve clinical status or modulate key Nrf2 targets in patients with CAP primarily due to SARS-CoV-2 infection.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00917-2023","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T17:15:37Z","timestamp":1709226937000},"page":"00917-2023","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["SFX-01 in hospitalised patients with community-acquired pneumonia during the COVID-19 pandemic: a double-blind, randomised, placebo-controlled trial"],"prefix":"10.1183","volume":"10","author":[{"given":"Merete B.","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Abo-Leyah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Hui","family":"Giam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thenmalar","family":"Vadiveloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7197-701X","authenticated-orcid":false,"given":"Holly R.","family":"Keir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pembridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Alferes De Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0337-9189","authenticated-orcid":false,"given":"Lilia","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Inglis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Gilmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Gierlinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.M.","family":"New","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albena T.","family":"Dinkova-Kostova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"2024101712165944000_10.2.00917-2023.1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"Suppl. 7","key":"2024101712165944000_10.2.00917-2023.2","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1093\/infdis\/jiz053","article-title":"Global and regional burden of hospital admissions for pneumonia in older adults: a systematic review and meta-analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J Infect Dis"},{"key":"2024101712165944000_10.2.00917-2023.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2588-y"},{"key":"2024101712165944000_10.2.00917-2023.4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024101712165944000_10.2.00917-2023.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0"},{"key":"2024101712165944000_10.2.00917-2023.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01109-6"},{"key":"2024101712165944000_10.2.00917-2023.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00048-2021"},{"key":"2024101712165944000_10.2.00917-2023.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"2024101712165944000_10.2.00917-2023.9","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1093\/cid\/ciab079","article-title":"The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States","volume":"73","author":"Moghadas","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024101712165944000_10.2.00917-2023.10","doi-asserted-by":"crossref","first-page":"2200803","DOI":"10.1183\/13993003.00803-2022","article-title":"Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline","volume":"60","author":"Roche","year":"2020","journal-title":"Eur Respir J"},{"key":"2024101712165944000_10.2.00917-2023.11","doi-asserted-by":"crossref","first-page":"100473","DOI":"10.1016\/j.lanepe.2022.100473","article-title":"Incidence of community acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: a prospective cohort study","volume":"21","author":"Hyams","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2024101712165944000_10.2.00917-2023.12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1513\/AnnalsATS.202102-209ST","article-title":"Understanding the host in the management of pneumonia. An official American Thoracic Society workshop report","volume":"18","author":"Dela Cruz","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2024101712165944000_10.2.00917-2023.13","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.016003534.x"},{"key":"2024101712165944000_10.2.00917-2023.14","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2012-0161OC"},{"key":"2024101712165944000_10.2.00917-2023.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2003.08.015"},{"key":"2024101712165944000_10.2.00917-2023.16","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.26.2.4501"},{"key":"2024101712165944000_10.2.00917-2023.17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11624"},{"key":"2024101712165944000_10.2.00917-2023.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600043"},{"key":"2024101712165944000_10.2.00917-2023.19","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1038\/s41467-020-18764-3","article-title":"SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate","volume":"11","author":"Olagnier","year":"2020","journal-title":"Nat Commun"},{"key":"2024101712165944000_10.2.00917-2023.20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s42003-022-03189-z","article-title":"Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice","volume":"5","author":"Ordonez","year":"2022","journal-title":"Commun Biol"},{"key":"2024101712165944000_10.2.00917-2023.21","doi-asserted-by":"publisher","DOI":"10.1021\/tx100389r"},{"key":"2024101712165944000_10.2.00917-2023.22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.6.2399"},{"key":"2024101712165944000_10.2.00917-2023.23","first-page":"4911","article-title":"Protective mechanism of sulforaphane in Nrf2 and anti-lung injury in ARDS rabbits","volume":"15","author":"Sun","year":"2018","journal-title":"Exp Ther Med"},{"key":"2024101712165944000_10.2.00917-2023.24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002042"},{"key":"2024101712165944000_10.2.00917-2023.25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12931-015-0253-z","article-title":"Sulforaphane improves the bronchoprotective response in asthmatics through Nrf2-mediated gene pathways","volume":"16","author":"Brown","year":"2015","journal-title":"Respir Res"},{"key":"2024101712165944000_10.2.00917-2023.26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.msard.2019.02.027","article-title":"SFX-01 reduces residual disability after experimental autoimmune encephalomyelitis","volume":"30","author":"Galea","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2024101712165944000_10.2.00917-2023.27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00018-022-04609-3","article-title":"Sulforaphane prevents and reverses allergic airways disease in mice via anti-inflammatory, antioxidant, and epigenetic mechanisms","volume":"79","author":"Royce","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"2024101712165944000_10.2.00917-2023.28","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/ph14111082","article-title":"Multiple antitumor molecular mechanisms are activated by a fully synthetic and stabilized pharmaceutical product delivering the active compound sulforaphane (SFX-01) in preclinical model of human glioblastoma","volume":"14","author":"Colapietro","year":"2021","journal-title":"Pharmaceuticals"},{"key":"2024101712165944000_10.2.00917-2023.29","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-14-0103"},{"key":"2024101712165944000_10.2.00917-2023.30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah4477"},{"key":"2024101712165944000_10.2.00917-2023.31","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24193593"},{"key":"2024101712165944000_10.2.00917-2023.32","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1038\/s41598-020-62714-4","article-title":"Biomarker exploration in human peripheral blood mononuclear cells for monitoring sulforaphane treatment responses in autism spectrum disorder","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"2024101712165944000_10.2.00917-2023.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01329-2"},{"key":"2024101712165944000_10.2.00917-2023.34","doi-asserted-by":"crossref","first-page":"e0245986","DOI":"10.1371\/journal.pone.0245986","article-title":"The anti-arthritis effect of sulforaphane, an activator of Nrf2, is associated with inhibition of both B cell differentiation and the production of inflammatory cytokines","volume":"16","author":"Moon","year":"2021","journal-title":"PLoS One"},{"key":"2024101712165944000_10.2.00917-2023.35","doi-asserted-by":"crossref","first-page":"805508","DOI":"10.3389\/fphar.2022.805508","article-title":"Sulforaphane ameliorates the severity of psoriasis and SLE by modulating effector cells and reducing oxidative stress","volume":"13","author":"Du","year":"2022","journal-title":"Front Pharmacol"},{"key":"2024101712165944000_10.2.00917-2023.36","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2010-0321OC"},{"key":"2024101712165944000_10.2.00917-2023.37","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/nu13020602","article-title":"Examination of novel immunomodulatory effects of L-sulforaphane","volume":"13","author":"Mazarakis","year":"2021","journal-title":"Nutrients"},{"key":"2024101712165944000_10.2.00917-2023.38","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41586-021-03925-1","article-title":"Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies","volume":"598","author":"Lempp","year":"2021","journal-title":"Nature"},{"key":"2024101712165944000_10.2.00917-2023.39","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/infdis\/jiaa724","article-title":"Monocyte CD169 expression as a biomarker in the early diagnosis of coronavirus disease 2019","volume":"223","author":"Bedin","year":"2021","journal-title":"J Infect Dis"},{"key":"2024101712165944000_10.2.00917-2023.40","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0934"},{"key":"2024101712165944000_10.2.00917-2023.41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12931-016-0406-8","article-title":"A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation","volume":"17","author":"Duran","year":"2016","journal-title":"Respir Res"},{"key":"2024101712165944000_10.2.00917-2023.42","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jaip.2016.03.012","article-title":"A randomized controlled trial of the effect of broccoli sprouts on antioxidant gene expression and airway inflammation in asthmatics","volume":"4","author":"Sudini","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101712165944000_10.2.00917-2023.43","doi-asserted-by":"crossref","first-page":"e0163716","DOI":"10.1371\/journal.pone.0163716","article-title":"Lack of effect of oral sulforaphane administration on Nrf2 expression in COPD: a randomized, double-blind, placebo controlled trial","volume":"11","author":"Wise","year":"2016","journal-title":"PLoS One"},{"key":"2024101712165944000_10.2.00917-2023.44","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.3390\/nu13124559","article-title":"Investigating the potential for sulforaphane to attenuate gastrointestinal dysfunction in mdx dystrophic mice","volume":"13","author":"Swiderski","year":"2021","journal-title":"Nutrients"},{"key":"2024101712165944000_10.2.00917-2023.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.01.025"},{"key":"2024101712165944000_10.2.00917-2023.46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0808346105"},{"key":"2024101712165944000_10.2.00917-2023.47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tips.2022.12.003","article-title":"Advances and challenges in therapeutic targeting of NRF2","volume":"44","author":"Dinkova-Kostova","year":"2023","journal-title":"Trends Pharmacol Sci"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00917-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:34:16Z","timestamp":1740375256000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00917-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3,11]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1183\/23120541.00917-2023"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00917-2023","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}